Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype

Hoppe, S.; Noseir, S.; Yazbeck, A.; Zaburannyi, N.; Grossbach, J.; Lyu, S.I.; Velazquez Camacho, O.; Müller, S.; Gebauer, F.; Richartz, V.; Holz, B.; Berg, J.; Achter, V.; Altmüller, J.; Becker, K.; Arolt, C.; Meder, L.; Zhao, Y.; Schlößer, H.; Baus, W.W.; Kamp, F.; Baues, C.; Beyer, A.; Odenthal, M.; Quaas, A.; Buettner, R.; Hillmer, A.M.

Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype

Tools

Preview	PDF (Preprint) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 9MB
	Other (Supplementary Material) 14MB

Item Type:	Preprint
Title:	Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype
Creators:	Hoppe, S., Noseir, S., Yazbeck, A., Zaburannyi, N., Grossbach, J., Lyu, S.I., Velazquez Camacho, O., Müller, S., Gebauer, F., Richartz, V., Holz, B., Berg, J., Achter, V., Altmüller, J. ORCID: https://orcid.org/0000-0003-4372-1521, Becker, K., Arolt, C., Meder, L., Zhao, Y., Schlößer, H., Baus, W.W., Kamp, F., Baues, C., Beyer, A. ORCID: https://orcid.org/0000-0002-3891-2123, Odenthal, M., Quaas, A., Buettner, R. and Hillmer, A.M. ORCID: https://orcid.org/0000-0002-3381-7266
Abstract:	Neoadjuvant chemoradiation therapy (RCT) is a frequently used treatment regimen for esophageal adenocarcinoma (EAC); however, the response varies dramatically, and resistance is a clinical challenge. We aimed to identify the molecular mechanisms underlying RCT resistance. We established a mouse xenograft RCT model with human EAC cell lines representing different response groups, and tested enhanced genomic instability as a potential evolutionary modulator by reducing BRCA2 function. Xenografts that relapsed after RCT displayed upregulation of stress response keratins, including KRT6 and KRT16 connected with a basal-like transcriptomic/ proteomic phenotype. We screened our cohort of 728 patients with EAC and found significantly shorter overall survival for patients with KRT6-high tumors, driven by patients receiving neoadjuvant treatment. Overall, we identified a basal-like cell state in EAC that reflects RCT relapse. The basal-like subtype is a marker of treatment failure, providing a new avenue for translational research to overcome RCT resistance.
Keywords:	Esophageal Adenocarcinoma, Chemoradiation Therapy, Resistance, Adaptation, Tumor Evolution, Basal-Like, Animals, Mice
Source:	bioRxiv
Publisher:	Cold Spring Harbor Laboratory Press
Article Number:	2025.01.28.635332
Date:	1 February 2025
Official Publication:	https://doi.org/10.1101/2025.01.28.635332

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year